# E-DRUG: Anti retrovirals (cont) **URL:** \ **Category:** e-drug\ **Created:** [October 25, 1999, 9:35pm UTC](https://talk.edrugplus.org/t/e-drug-anti-retrovirals-cont/6431 "1999-10-25T21:35:31Z")\ **Posts on this page:** 1\ **Page:** 1
**Author:** ![Carolyn\_Green3](https://avatars.discourse-cdn.com/v4/letter/c/3ab097/32.png) [@Carolyn\_Green3](https://talk.edrugplus.org/u/Carolyn_Green3)\ **Post date:** [October 25, 1999, 9:35pm UTC](https://talk.edrugplus.org/t/e-drug-anti-retrovirals-cont/6431/1 "1999-10-25T21:35:31Z")
E-drug: Anti retrovirals (cont) --------------------------------------------- Now I am really confused. Messages about generic AZT/zidovudine from Leo Offerhaus and Richard Laing on the one side, and from David Scondras and Khalil Elouardighi on the other side, conflict so much that I don't know any more what to advise people. This week I have to talk to some British members of parliament about TRIPS, compulsory licensing and access to treatment for HIV in developing countries - what should I tell them? This is not an academic debate, it is about a tragic reality for 95 percent of the people who live with HIV/|AIDS. If planning and advocacy for the future is to be successful or even possible, the essential drugs experts and the HIV experts should be pooling their knowledge and evidence as a priority, and making it readily available via both the essential drugs AND the HIV networks. Together, we need to be able to work out some sustainable methods of improving access to drugs. We need hard facts and evidence to do this, not rhetoric. IS there anyone out there who is scientifically expert enough in drug formulation and production AND who understands the effects of the AIDs epidemic, who can shed some light on the situation? Please help. Carolyn Green Consulting Pharmacist 3 Leslie Grove Psychotherapist Croydon Surrey CR0 6TJ UK tel: +44(0) 20 8686 3831 e-mail: greencm@dial.pipex.com -- Send mail for the `E-Drug' conference to `e-drug@usa.healthnet.org'. Mail administrative requests to `majordomo@usa.healthnet.org'. For additional assistance, send mail to: `owner-e-drug@usa.healthnet.org'.